Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2026-09-17 17:19:45 ET · period of report 2026-09-16 · accession 0001159036-26-000123 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-17 17:19 | 2026-09-16 | HALO | Posard Matthew L. | Dir | S - Sale | $107.74 | -19.0K | 58.8K | -24% | -$2.05M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-16 | S | D | 3,100 | $106.13 | 74,735 | D | — | — | (F1) The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. (F2) Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.550 to $106.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 2 | Common | Common Stock | 2026-09-16 | S | D | 3,000 | $106.83 | 71,735 | D | — | — | (F1) The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. (F3) Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.580 to $107.310. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2026-09-16 | S | D | 8,896 | $108.04 | 62,839 | D | — | — | (F1) The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. (F4) Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.600 to $108.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2026-09-16 | S | D | 4,000 | $108.99 | 58,839 | D | — | — | (F1) The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. (F5) Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.605 to $109.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |